

Reference Data

Fiscal Year 2016
(April 1, 2016 to March 31, 2017)

Consolidated Earnings

• Consolidated Financial Data	P .1
• Consolidated Balance Sheets	P .2
• Consolidated P/L Statement	P .3
• Consolidated Sales Breakdown by Segment/Category	P .4
• Consolidated Operating Income by Segment	P .4
• Consolidated Sales - Leading Brands of Self-Medication Operations	P .5
• Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations	P .6
• Capital Expenditure	P .7
• Depreciation and Amortization	P .7
• R&D Expenses	P .7
• Results of Major Consolidated Subsidiaries	
♦ Taisho Pharmaceutical	P .8
♦ Taisho Toyama Pharmaceutical	P .8
♦ Biofermin Pharmaceutical	P .8
• Major Subsidiaries and Affiliates	P .9
• Shareholders Information	P.10
• Prescription Pharmaceutical Operations: New Drug Development-Taisho Pharmaceutical	P.11
• Launch of New Products	P.14

Taisho Pharmaceutical Holdings Co.,Ltd.

Consolidated Financial Data

(Millions of yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17 (FY2016)	(Est.)	
					March 18(FY2017)	
					2Q(4-9)	Full year
Net sales	295,957	290,498	290,135	279,773	137,500	279,000
(YOY%)	(+3.8%)	(-1.8%)	(-0.1%)	(-3.6%)	(-2.5%)	(-0.3%)
Self-Medication operations	181,753	176,295	180,722	179,992	89,300	181,300
Prescription Pharmaceutical operations	114,204	114,202	109,413	99,781	48,200	97,700
Gross profit*	184,693	178,248	176,813	178,226	88,400	180,900
Selling, general and administrative expenses	143,009	146,273	147,935	146,260	76,900	152,400
Research and development expenses	21,874	21,554	21,768	21,260	12,400	24,000
(% Sales)	(7.4%)	(7.4%)	(7.5%)	(7.6%)	(9.0%)	(8.6%)
Advertising expenses	16,960	19,169	21,366	22,087	11,400	23,200
Sales promotion expenses	31,159	32,355	31,775	30,079	15,400	31,100
Personnel expenses	37,489	35,856	36,042	35,845	18,100	36,300
Operating income	41,683	31,974	28,878	31,966	11,500	28,500
(YOY%)	(+18.0%)	(-23.3%)	(-9.7%)	(+10.7%)	(-31.0%)	(-10.8%)
Ordinary income	51,244	39,576	36,775	38,036	14,500	34,500
(YOY%)	(+16.0%)	(-22.8%)	(-7.1%)	(+3.4%)	(-24.2%)	(-9.3%)
Profit attributable to owners of parent	32,692	24,528	22,473	28,781	10,500	24,000
(YOY%)	(+24.2%)	(-25.0%)	(-8.4%)	(+28.1%)	(-22.2%)	(-16.6%)
Comprehensive income	47,535	47,845	9,059	30,184	-	-
(YOY%)	(+7.8%)	(+0.7%)	(-81.1%)	(+233.2%)	-	-
EPS (yen)	403.18	302.57	277.75	360.18	131.41	300.38
EPS, diluted (yen)	403.07	302.42	277.59	359.92	131.32	300.17
BPS (yen)	7,401.61	7,892.19	7,870.04	8,127.87	8,200.44	8,319.97
Dividend per share (yen)**	110.00	110.00	100.00	110.00	50.00	110.00
Payout ratio	27.3%	36.4%	36.0%	30.5%	-	36.6%
Capital expenditure	10,401	5,253	8,967	7,011	2,260	5,790
Depreciation and amortization	11,042	11,561	11,117	10,423	5,000	10,300
Total assets	728,442	768,092	759,049	771,222	777,000	787,000
Shareholders' equity	611,933	653,242	643,127	665,088	671,000	681,000
Return on equity (%)**	5.6%	4.0%	3.5%	4.5%	-	3.7%
Return on assets (%)**	4.7%	3.3%	2.9%	3.8%	-	3.1%
Equity ratio (%)	82.4%	83.3%	82.9%	84.2%	84.3%	84.5%
Overseas sales	25,393	27,949	29,901	27,529	14,310	29,520
Overseas sales ratio (% of total sales)	8.6%	9.6%	10.3%	9.8%	10.4%	10.6%
Number of employees	6,381	6,609	6,517	6,461	-	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

Consolidated Balance Sheets

(Millions of yen)

	End of FY2015		End of FY2016		change	
	(March 31, 16)	% total	(March 31, 17)	% total		
(Assets)						
I Current assets:	319,670	42.1%	308,946	40.1%	-10,724	
Cash and deposits	172,142		201,275		+29,133	
Notes and accounts receivable-trade	75,243		69,535		-5,707	
Marketable securities	34,316		-		-34,316	Bond redemptions -34,200
Inventories	26,638		27,501		+862	
Deferred tax assets	6,128		5,819		-308	
Others	5,201		4,814		-386	
II Fixed assets:	439,379	57.9%	462,276	59.9%	+22,897	
(1) Tangible fixed assets:	98,950	(13.0%)	97,282	(12.6%)	-1,667	
Buildings and structures	45,979		49,957		+3,977	Completion of Omiya Distribution Center 2
Machinery and equipment	7,211		6,372		-839	
Land	37,473		37,457		-16	
Others	8,285		3,496		-4,789	
(2) Intangible fixed assets:	38,863	(5.1%)	34,372	(4.5%)	-4,490	
Goodwill	19,046		16,768		-2,277	
Sales rights	4,675		4,068		-606	
Trademarks	12,175		9,966		-2,209	
Software	2,419		3,046		+626	
Others	547		523		-23	
(3) Investments and other assets:	301,565	(39.7%)	330,620	(42.9%)	+29,055	
Investments in securities	237,213		252,459		+15,246	
Affiliates' stocks	54,590		67,550		+12,960	Acquisition of shares of Duoc Hau Giang Pharmaceutical JSC
Net defined benefit assets	568		2,496		+1,927	
Deferred tax assets	7,869		6,783		-1,085	
Others	1,322		1,330		+7	
Total assets	759,049	100.0%	771,222	100.0%	+12,173	
(Liabilities)						
I Current liabilities:	66,646	8.8%	58,097	7.5%	-8,548	
Notes and accounts payable-trade	27,082		23,327		-3,755	
Accounts payable	16,753		13,047		-3,706	
Accrued corporate tax	5,746		5,774		+28	
Allowance for bonuses	3,855		3,854		-1	
Others	13,207		12,094		-1,113	
II Long-term liabilities:	49,275	6.5%	48,036	6.2%	-1,239	
Net defined benefit liabilities	23,713		23,505		-208	
Deferred taxes liabilities	16,333		16,130		-202	
Others	9,228		8,400		-828	
Total liabilities	115,922	15.3%	106,134	13.8%	-9,787	
(Net assets)						
I Shareholders' equity	600,862	79.2%	621,583	80.6%	+20,720	
Common stock	30,000	4.0%	30,000	3.9%	-	
Additional paid-in capital	15,271	2.0%	15,272	2.0%	+0	
Retained earnings	623,255	82.1%	644,038	83.5%	+20,783	Profit attributable to owners of parent +28,781 Dividend on retained earnings -7,997
Treasury stock	-67,664	-8.9%	-67,277	-8.8%	-63	
II Accumulated other comprehensive income	28,029	3.7%	27,875	3.6%	-153	
Unrealized gain on securities	35,736	4.7%	36,234	4.7%	+498	
Deferred gains or losses on hedges	-0	- 0.0%	-0	0.0%	+0	
Foreign currency adjustment accounts	507	0.1%	-2,195	-0.3%	-2,702	
Remeasurements of defined benefit plans	-8,213	-1.1%	-6,162	-0.8%	+2,050	
III Subscription rights to shares	357	0.0%	478	0.1%	+121	
IV Minority interest	13,878	1.8%	15,150	2.0%	+1,272	
Total net assets	643,127	84.7%	665,088	86.2%	+21,960	
Total liabilities and net assets	759,049	100.0%	771,222	100.0%	+12,173	

Consolidated P/L Statement

(Millions of yen)

	FY2015		FY2016		YOY change	
		% Sales		% Sales		
Net sales	290,135	100.0%	279,773	100.0%	-10,362	
Cost of sales	113,143	39.0%	101,525	36.3%	-11,618	
Gross profit on sales	176,991	61.0%	178,248	63.7%	+1,256	
Provision for sales returns	178		22		-156	
Gross profit	176,813	60.9%	178,226	63.7%	+1,412	
Selling, general and administrative expenses	147,935	51.0%	146,260	52.3%	-1,675	
Research and development expenses	21,768		21,260		-507	
Advertising expenses	21,366		22,087		+720	
Sales promotion expenses	31,775		30,079		-1,695	
Personnel expenses	36,042		35,845		-196	
Others	36,983		36,987		+3	
Operating income	28,878	10.0%	31,966	11.4%	+3,088	
Non-operating income	8,068	2.8%	7,511	2.7%	-556	(Previous year) Equity in earnings of entities accounted for using equity method: +382
Non-operating expenses	170	0.1%	1,441	0.5%	+1,271	Equity in losses of affiliates
Ordinary income	36,775	12.7%	38,036	13.6%	+1,260	
Extraordinary gains	19	0.0%	4,138	1.5%	+4,118	Gain on sales of fixed assets 4,123
Extraordinary losses	985	0.3%	217	0.1%	-767	(Previous year) Loss on disposal of fixed assets 850
Income before income taxes and minority interests	35,809	12.3%	41,956	15.0%	+6,147	
Income taxes	11,927	4.1%	11,750	4.2%	-176	
Income before minority interests	23,882	8.2%	30,205	10.8%	+6,323	
Minority interest gain of consolidated subsidiaries	1,408	0.5%	1,424	0.5%	+16	
Profit attributable to owners of parent	22,473	7.7%	28,781	10.3%	+6,307	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17 (FY2016)	(Est.) March 18(FY2017)	
					2Q(4-9)	Full year
					Self-Medication operations (YOY%)	181,753 (+6.1%)
Japan	153,856	145,614	148,125	149,733	73,600	149,300
Overseas	25,379	27,939	29,875	27,507	14,300	29,500
Others	2,516	2,741	2,721	2,751	1,400	2,500
Prescription Pharmaceutical operations (YOY%)	114,204 (+0.3%)	114,202 (-0.0%)	109,413 (-4.2%)	99,781 (-8.8%)	48,200 (-4.7%)	97,700 (-2.1%)
Ethical drugs	111,289	111,594	107,215	96,126	46,800	95,100
Other	2,914	2,608	2,197	3,655	1,400	2,600
Total	295,957	290,498	290,135	279,773	137,500	279,000

Consolidated Operating Income by Segment

(Millions of yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17 (FY2015)	(Est.) March 18(FY2017)	
					2Q(4-9)	Full year
					Self-Medication operations (YOY%)	36,865 (+10.0%)
Prescription Pharmaceutical operations (YOY%)	6,000 (+98.2%)	2,078 (-65.4%)	1,755 (-15.5%)	3,352 (+90.9%)	500 (-78.0%)	3,900 (+16.3%)
Other* (YOY%)	-1,181 (-)	-1,164 (-)	-1,271 (-)	-1,492 (-)	-700 (-)	-1,400 (-)
Total	41,683	31,974	28,878	31,966	11,500	28,500

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17		(Est.) March 18(FY2017)		
				(FY2016)	YOY	2Q(4-9)	Full year	YOY
Japan	153.9	145.6	148.1	149.7	+1.1%	73.6	149.3	-0.3%
Lipovitan series	67.5	62.1	60.5	58.5	-3.3%	31.4	56.8	-2.9%
Pabron series	26.0	25.2	24.8	26.3	+6.1%	10.5	26.9	+2.2%
RiUP series	15.6	14.9	16.5	16.1	-2.9%	7.7	15.9	-1.0%
Livita series	4.7	4.0	3.9	3.8	-2.1%	1.7	3.6	-5.6%
Gastrointestinal treatment series	4.3	4.1	4.1	4.0	-3.0%	1.8	3.9	-2.3%
VICKS series	3.2	3.5	3.6	3.6	+0.7%	1.5	4.2	+15.0%
NARON series	4.1	3.7	3.7	3.4	-8.3%	1.6	3.5	+4.1%
Colac series	3.6	3.3	3.3	3.3	-1.1%	1.6	3.3	+0.3%
Biofermin series	6.7	6.7	7.5	8.8	+18.3%	3.6	7.9	-10.6%
Overseas	25.4	27.9	29.9	27.5	-7.9%	14.3	29.5	+7.2%
Energy drinks	9.0	9.4	10.3	9.4	-9.5%	5.0	9.9	+5.6%
OTC drugs	15.5	17.6	18.4	17.2	-6.7%	8.7	18.3	+6.6%
Others	2.5	2.7	2.7	2.8	+1.1%	1.4	2.5	-9.1%

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17		(Est.) March 18(FY2017)		
				(FY2016)	YOY	2Q(4-9)	Full year	YOY
Lipovitan series	67.5	62.1	60.5	58.5	-3.3%	31.4	56.8	-2.9%
Lipovitan D	44.3	40.0	38.6	37.2	-3.5%	20.4	36.1	-3.1%
Others	23.2	22.1	21.9	21.3	-3.1%	11.0	20.7	-2.5%
(100mL other Lipovitans)	15.2	14.5	13.9	13.5	-3.0%	7.1	13.2	-2.3%
(50mL other Lipovitans)	8.0	7.6	8.0	7.7	-3.2%	3.9	7.5	-2.8%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17		(Est.) March 18(FY2017)		
				(FY2016)	YOY	2Q(4-9)	Full year	YOY
Edirol	14.1	17.2	19.8	22.6	+13.9%	12.3	25.0	+10.6%
ZOSYN	25.4	26.9	27.3	15.5	-43.2%	5.6	9.5	-38.8%
Clarith	16.4	13.5	12.0	9.3	-22.3%	3.7	8.5	-8.8%
Bonviva	1.2	3.6	4.9	5.9	+19.9%	3.4	7.1	+20.1%
Palux	7.9	7.0	6.2	5.4	-13.7%	2.5	4.8	-10.4%
Geninax	6.8	5.7	4.3	5.2	+21.3%	2.0	4.5	-13.5%
OZEX	7.2	6.6	5.9	4.9	-16.3%	2.1	4.7	-4.3%
Biofermin	3.7	3.6	3.6	3.9	+10.4%	2.1	4.2	+6.9%
Lusefi	-	2.4	0.9	2.9	+225.2%	2.1	4.8	+67.1%
LOQQA	-	-	0.4	1.8	+315.2%	1.6	3.6	+98.5%

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17 (FY2016)	(Est.)	
					March 18 (FY2017)	
					2Q(4-9)	Full year
Total capital expenditure	10,401	5,253	8,967	7,011	2,260	5,790
Taisho Pharmaceutical	6,683	4,222	7,324	6,013	1,860	4,590
Omiya Factory	812	920	868	947	400	1,040
Hanyu Factory	99	61	21	41	30	180
Okayama Factory	26	64	28	115	10	50
Research Center	1,726	1,879	1,053	893	450	1,050
Others	4,018	1,296	5,351	4,015	970	2,270
Other subsidiaries	3,718	1,031	1,642	998	400	1,200

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17 (FY2016)	(Est.)	
					March 18 (FY2017)	
					2Q(4-9)	Full year
Depreciation and amortization	11,042	11,561	11,117	10,423	5,000	10,300
Cost of sales	4,033	4,163	3,823	3,411	1,500	3,200
SGA expenses	7,009	7,398	7,293	7,011	3,500	7,100

Consolidated: R&D Expenses

(Millions of yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17 (FY2016)	(Est.)	
					March 18 (FY2017)	
					2Q(4-9)	Full year
Total R&D expenses	21,874	21,554	21,768	21,260	12,400	24,000
Self-Medication operations	5,790	5,502	5,497	5,497	3,400	6,400
Prescription Pharmaceutical operations	16,084	16,051	16,270	15,763	9,000	17,600

Results of Major Consolidated Subsidiaries

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17		(Est.) March 18(FY2017)		
				(FY2016)	YOY	2Q(4-9)	Full year	YOY
Net Sales	197	198	198	203	+2.4%	100	204	+0.6%
Self-Medication	149	147	150	152	+1.3%	74	151	-0.8%
Prescription Pharmaceutical	47	51	48	51	+5.8%	25	54	+4.6%
Operating income	32	21	20	23	+18.2%	7	19	-15.9%
Ordinary income	39	25	24	27	+9.0%	13	26	-3.6%
Profit	27	17	18	20	+12.5%	11	20	+0.5%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical

(Billions of Yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17		(Est.) March 18(FY2017)		
				(FY2016)	YOY	2Q(4-9)	Full year	YOY
Net Sales	107	112	107	96	-10.3%	47	95	-1.1%
Operating income	2	4	3	2	-23.5%	1	2	+11.6%
Ordinary income	3	4	3	2	-21.7%	1	2	+8.7%
Profit	1	2	1	1	-9.5%	1	1	+13.0%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical are included in the consolidated results of Prescription Pharmaceutical operator

Sales and earnings of Biofermin Pharmaceutical

(Billions of Yen)

	March 14 (FY2013)	March 15 (FY2014)	March 16 (FY2015)	March 17		(Est.) March 18(FY2017)		
				(FY2016)	YOY	2Q(4-9)	Full year	YOY
Net Sales	11	11	10	11	+9.8%	6	11	+0.0%
Self-Medication	7	7	7	7	+9.7%	4	7	-1.2%
Prescription Pharmaceutical	4	4	3	3	+10.1%	2	3	+2.6%
Operating income	3	3	2	3	+18.4%	2	3	+0.1%
Ordinary income	3	4	2	3	+16.5%	2	3	+0.8%
Profit	2	2	2	2	+19.5%	1	2	+0.1%

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of March 31, 2017)

Company	Address	Capital	Business	Ownership *
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 29,804,450	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	64.0
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70.3
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 163,000	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.0
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
(2) Equity accounting method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000,000	PD	34.0
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.1
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 871,643,300	SMG	24.4

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Shareholders Information (as of end of March 2017)

Major Shareholders

(Thousands of Shares)

Shareholders	Number of shares	% of total
The Uehara Memorial Foundation	15,000	18.76%
Shoji Uehara	7,874	9.85%
Uehara Museum	3,900	4.88%
Sumitomo Mitsui Banking Corp.	3,000	3.75%
The Bank of Tokyo-Mitsubishi UFJ, Ltd.	3,000	3.75%
Akira Uehara	2,143	2.68%
Sumitomo Chemical Co., Ltd.	1,779	2.23%
Kajima Corporation	1,650	2.06%
Japan Trustee Services Bank, Ltd. (Trust account)	1,567	1.96%
Japan Trustee Services Bank, Ltd. (Sumitomo Mitsui Trust Bank, Limited ReTrust Account/ Sumitomo Chemical Company, Limited Employee Pension Trust Account)	1,530	1.91%

Shares less than one thousand are rounded down.

Treasury stock of 10,165 thousand shares are excluded from the above as these shares do not have voting right

The shareholding ratio is calculated excluding treasury stock. (Rounded to the nearest second decimal place)

Distribution of Ownership Among Shareholders

	% of total
Financial Institutions	20.57%
Financial Instruments Firms	0.73%
Other companies	40.38%
Foreign Companies	12.07%
Individuals and Others	26.25%
Total	100.00%

The shareholder composition is calculated excluding treasury stock of 10,165 thousand shares.

(Rounded to the nearest second decimal place)

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 15, 2017

In Japan

Phase 2

TS-091 (Oral)

< Application > Central disorders of hypersomnolence
< Development > In-house

TS-152 (Injection)

< Application > Rheumatoid arthritis
< Development > In-license (Licensor: Ablynx)
< Description > Anti-TNF(Tumor Necrosis Factor)- α antibody
< Remarks > Generic name: Ozoralizumab

TS-141 (Oral)

< Application > Childhood Attention-Deficit/Hyperactivity Disorder
< Development > In-house

TS-133 (Topical)

< Application > Alopecia
< Development > In-house

TS-142 (Oral)

< Application > Insomnia
< Development > In-house

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 15, 2017

Overseas

Phase 2

TS-121 (Oral)

< Target disease > Depression
< In-house/Licensed-in > In-house

Phase 1

TS-071 (Oral)

< Target disease > Type 2 diabetes
< In-house/Licensed-in > In-house
< Description > Sodium-glucose cotransporter 2 (SGLT2) inhibitor
< Remarks > Generic name: Luseogliflozin Hydrate
In Japan: Launched on May 23, 2014 (Product name: Lusefi)

TS-091 (Oral)

< Target disease > Central disorders of hypersomnolence
< In-house/Licensed-in > In-house

TS-134 (Oral)

< Target disease > Schizophrenia
< In-house/Licensed-in > In-house

Prescription Pharmaceutical Operations:
New Drug Development - Taisho Pharmaceutical

As of May 15, 2017

Changes Since FY2016 3Q Earnings Announcement (February 2, 2017)

In Japan: TS-142 (Oral)

< Application > Insomnia

< Development > In-house

< Changes > Added to Phase 2 in Japan

Overseas: TS-121 (Topical)

< Application > Depression

< Development > In-house

< Changes > Transfer to Phase 2

Launch of New Products

As of May 15, 2017

New Products Since FY2016 3Q Earnings Announcement (February 2, 2017)

Self-Medication Operations

Lipovitan D limited-edition Japanese professional baseball teams bottle

- < Description > These Lipovitan D limited-edition bottles feature designs based on the logos of Japanese professional baseball teams.
Sold at convenience stores and other locations centered on the home towns of ten Japanese professional baseball teams.
Inspired by the communication concept "Have a Dream," the limited-edition bottles will support people who are working hard to realize their dreams.
- < Launch > Since March 2017
-

COBARASAPŌTO Muscat Flavor

- < Description > When consumed on an empty stomach, this product suppresses hunger by creating a sense of fullness in the stomach. For this reason, the product is recommended to people who have given up on diets in the past due to hunger or those who want to continue their diets enjoyably.
- < Launch > March 2017
-

Green Tea for People with Slightly Elevated Triglycerides

- < Description > Classified as a Food for Specified Health Uses (FOSHU), this powdered green tea beverage is optimal for people who tend to consume a lot of fatty foods or those who have slightly elevated triglyceride levels. Its functional substance is monoglucosyl hesperidin, which acts to lower triglycerides.
- < Launch > March 2017
-

Green Tea for People Concerned About Their Blood Sugar Levels After Meals

- < Description > Classified as a Food for Specified Health Uses (FOSHU), this powdered green tea beverage is optimal for people concerned about their blood sugar levels after meals. Its functional substance is indigestible dextrin, which acts to moderate the absorption of sugars in meals.
- < Launch > March 2017
-

AVALON

- < Description > This gastrointestinal treatment, which is classified as a Category 2 medicine (an item eligible for the self-medication tax deduction system), helps to relieve heartburn due to gastric reflux and other causes, and stomachache. It contains an antacid, a gastric acid secretion suppressant, and a gastric mucosal protection and restoration ingredient.
- < Launch > April 2017
-

Launch of New Products

As of May 15, 2017

Self-Medication Operations

RAIZIN DRY & RAIZIN MILD

< Description > This innovative carbonated beverage is packaged in a single-serve-size 185 ml can developed jointly with the design office “nendo,” led by the world-renowned designer Oki Sato.

Sold at convenience stores and shops in train stations, as well as via Taisho Pharmaceutical Direct, a mail order and direct sales service.

< Launch > April 2017
